Poseida Therapeutics to Present Phase 1 Data on CAR-T P-BCMA-ALLO1 in Relapsed/Refractory Multiple Myeloma at IMS Annual Meeting

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in allogeneic cell therapy and genetic medicines, has announced important developments regarding its investigational allogeneic CAR-T cell therapy, P-BCMA-ALLO1. This innovative treatment targets B-cell maturation antigen (BCMA) specifically for patients suffering from relapsed or refractory multiple myeloma. The announcement highlights the presentation of new clinical data at the 21st International Myeloma Society (IMS) Annual Meeting in Rio de Janeiro, as well as the initiation of a Phase 1b clinical trial for the therapy.

The IMS Annual Meeting, which takes place from September 25-28, 2024, will feature an oral presentation of the ongoing Phase 1 study of P-BCMA-ALLO1. The presentation, titled "OA – 04: A Phase 1 Study of P-BCMA-ALLO1, a Non-viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM)," will be delivered by Dr. Bhagirathbhai R. Dholaria from Vanderbilt University Medical Center. The presentation is scheduled for September 27, 2024, at 5:42 PM local time.

Dr. Syed Rizvi, Chief Medical Officer of Poseida Therapeutics, emphasized the need for effective off-the-shelf therapies for multiple myeloma, a cancer that remains incurable despite recent advances. Dr. Rizvi expressed optimism about P-BCMA-ALLO1's potential to offer clinical benefits to patients with relapsed or refractory conditions. Poseida also announced the commencement of the Phase 1b portion of the study, which aims to explore the therapy's promise further.

In tandem with the Phase 1b trial initiation, Poseida will receive a $20 million payment from its partner, Roche, upon reaching this milestone. The ongoing collaboration between Poseida and Roche involves refining the trial design based on feedback from advisory board meetings with leading clinicians. Poseida remains responsible for the expanded Phase 1/1b trial, which Roche will fund.

P-BCMA-ALLO1 is an innovative off-the-shelf CAR-T cell therapy enriched with stem cell memory T cells (TSCM) and utilizes a VH-based binder targeting BCMA. The therapy is designed to address the unmet needs of multiple myeloma patients who have limited options due to relapses and refractory conditions. Initial clinical data presented at the American Society of Hematology (ASH) meeting in December 2023 supported the efficacy and safety of this approach.

Poseida Therapeutics, Inc. is committed to advancing novel allogeneic cell therapies and genetic medicines, aiming to cure certain types of cancer and rare diseases. The company's pipeline includes investigational CAR-T therapies for both solid tumors and blood cancers, as well as in vivo genetic medicines addressing high unmet medical needs. Poseida employs proprietary genetic editing platforms, including the piggyBac® DNA Delivery System and the Cas-CLOVER™ Site-Specific Gene Editing System. The company also boasts in-house GMP cell therapy manufacturing capabilities. Poseida has formed strategic partnerships with Roche and Astellas to harness the potential of cell therapies for cancer patients.

In summary, the latest developments in Poseida's P-BCMA-ALLO1 program mark significant progress in the treatment of multiple myeloma. The ongoing clinical trials and collaborations with industry leaders like Roche underscore the potential of this innovative therapy to provide new hope for patients with relapsed or refractory multiple myeloma.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!